Side Effects of tenofovir disoproxil fumarate/tenofovir alafenamide: A Synthesis of Findings from 28 Studies

  1. Home
  2. Side Effects of tenofovir disoproxil fumarate/tenofovir alafenamide
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of tenofovir disoproxil fumarate/tenofovir alafenamide: A Synthesis of Findings from 28 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of tenofovir disoproxil fumarate/tenofovir alafenamide: A Synthesis of Findings from 28 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Tenofovir disoproxil fumarate (TDF) has been a widely used drug for HIV treatment, but it has been reported to have side effects such as kidney problems and decreased bone density. Tenofovir alafenamide (TAF) is a newer formulation of TDF that is expected to reduce the risk of these side effects. 28 , 17 , 12

Several studies have shown that TAF has less impact on the kidneys and bones compared to TDF, while maintaining similar antiviral efficacy. 27 , 20 , 26 , 19 , 24 , 16 , 14 , 18

On the other hand, TAF has been reported to have a higher risk of weight gain compared to TDF. 7

Reasons for Side Effects

The reason why TAF has less impact on the kidneys and bones compared to TDF is thought to be because TAF is effective at lower doses than TDF. 27 , 17

The reason why TAF has a higher risk of weight gain is not fully understood, but it is thought to be due to mitochondrial toxicity or effects on appetite. 7

Common Side Effects

Kidney Effects

TDF has been a concern for kidney effects, but TAF is considered to be a safer drug with less impact on the kidneys compared to TDF. 27 , 17 , 23 , 14 , 25 , 11 , 4 , 1

Decreased Bone Density

TDF has been a concern for decreased bone density, but TAF is thought to reduce the risk of decreased bone density compared to TDF. 27 , 23 , 17 , 14 , 12 , 1

Weight Gain

TAF has been reported to have a higher risk of weight gain compared to TDF. 7

Other Side Effects

TAF has been reported to have other side effects compared to TDF. 23 , 15 , 2

Countermeasures for Side Effects

Kidney Effects

Regular blood tests to monitor kidney function are important to prevent kidney problems. 14 , 10

Decreased Bone Density

It is important to take calcium and vitamin D to prevent decreased bone density. 14

Weight Gain

It is important to follow a diet and exercise program to prevent weight gain. 7

Comparison Between Studies

Commonalities Among Studies

Many studies have shown that TAF has less impact on the kidneys and bones compared to TDF. 28 , 27 , 17 , 23 , 14 , 12

Differences Between Studies

Some studies have shown that TAF has a higher risk of weight gain compared to TDF. 7

Points to Note for Real-World Applications

TAF is expected to have less impact on the kidneys and bones compared to TDF, but it has also been reported to have a higher risk of weight gain. 28 , 27 , 17 , 23 , 14 , 12 , 7

Therefore, it is important to follow your doctor's instructions and have regular blood tests when taking TAF. 14 , 10

Limitations of Current Research

Research on TAF is still limited, and the long-term safety is not fully understood. 22 , 17

Future Research Directions

Further research is needed to evaluate the long-term safety and efficacy of TAF. 22

Conclusion

TAF is expected to have less impact on the kidneys and bones compared to TDF, but it has also been reported to have a higher risk of weight gain. 28 , 27 , 17 , 23 , 14 , 12 , 7

It is important to follow your doctor's instructions and have regular blood tests when taking TAF. 14 , 10

Further research is needed to evaluate the long-term safety and efficacy of TAF. 22

Keywords
Benefit Keywords
CHB treatment
ETV efficacy
TAF efficacy
1
Bone mineral density
HIV viral suppression
Weight gain
2
High resistance barriers
High safety profile
3
Hepatitis B treatment
Reduced renal toxicity
4
Durable treatment
Effective for HIV
5
CAB-LA
HIV prevention
6
Weight management
7
E/C/F/TAF
EFV-based regimen replacement
Neuropsychiatric toxicity
8
Renal safety
9
Improved renal parameters
10
HIV-1 treatment
TAF
renal and bone outcomes
11
Improved bone health
Improved renal function
12
Improved HIV treatment
13
HIV treatment
Improved antiretroviral therapy
Tolerable tenofovir formulations
14
Hepatitis B treatment
15
HIV treatment
STR treatment
16
HIV treatment improvement
Improved safety profile
17
HIV treatment
18
Avoid drug interactions
Avoid unwanted side effects
High barrier to resistance
Simplified once-daily
single-tablet regimen
19
Efficacy
No treatment-emergent resistance
Similar bone
renal
and lipid profiles
Tolerability
20
CHB treatment
21
Nucleoside analogues for CHB
TAF renal and bone safety
22
Better clinical outcomes
Faster virologic suppression
Fewer side effects
Improved adherence
Reduced drug interactions
Reduced resistance
23
Reduced pill burden
Single-tablet regimen
24
Hepatitis B treatment
Viral suppression
25
Manage HIV-1 infection
26
Improved bone safety
Improved renal safety
Viral suppression
27
Reduced side effects
28
Risk Keywords
Bone tissue
Renal function
1
Anxiety
Insomnia
Iridocyclitis
Pulmonary tuberculosis
Uveitis
2
Bone issues
Kidney dysfunction
Metabolic issues
3
Discontinuation risk
5
Price premium
6
Mitochondrial toxicity
Weight gain
7
Adverse events
9
CKD risk
Renal adverse effects
10
TAF side effects
acute kidney injury
11
Bone mineral density loss
Renal decline
12
Neuropsychiatric events
Weight gain
13
HIV resistance
Side effects
14
Abdominal pain
Fatigue
Headache
Nasopharyngitis
15
Comorbidities
Drug side effects
16
Drug resistance
21
Adefovir bone toxicity
Adefovir nephrotoxicity
Telbivudine muscular toxicity
22
Side effects
24
Fanconi syndrome
Hepatitis flares
Renal dysfunction
25
Bone mineral density loss
Metabolic effects
Renal impairment
26
Bone mineral density
Renal toxicity
28
Literature analysis of 28 papers
Positive Content
27
Neutral Content
1
Negative Content
0
Article Type
4
1
2
14
28
1.

Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.

Author: LiuZekun, ZhaoZhenzhen, MaXuefeng, LiuShousheng, XinYongning

CHB treatment
ETV efficacy
TAF efficacy
Bone tissue
Renal function

This meta-analysis found that long-term administration of tenofovir disoproxil fumarate (TDF) resulted in greater adverse effects on both renal function and bone tissue compared to entecavir (ETV) and tenofovir alafenamide fumarate (TAF) for chronic hepatitis B patients.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

2.

Effectiveness and safety of tenofovir alafenamide in children and adolescents living with HIV: a systematic review.

Author: O'RourkeJohn, TownsendClaire L, MilanziEdith, CollinsIntira Jeannie, CastroHannah, JuddAli, VicariMarissa, JessonJulie, LeroyValériane, PenazzatoMartina, RenaudFrançoise

Bone mineral density
HIV viral suppression
Weight gain
Anxiety
Insomnia
Iridocyclitis
Pulmonary tuberculosis
Uveitis

Tenofovir alafenamide (TAF)-containing regimens showed good viral suppression and no obvious safety concerns in children and adolescents living with HIV over 24-48 weeks. However, further research is needed to assess long-term safety and efficacy in this population.

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease.

Author: SinakosE, PanasP, FragkouN, AntoniadisN, KatsanosG, TsakniE, OikonomouT, NotopoulosA, TsoulfasG, GoulisI, AkriviadisE

Hepatitis B treatment
Reduced renal toxicity

This study aimed to evaluate the impact of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide fumarate (TAF) on renal function in post-liver transplantation (LT) patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV.

Author: TaramassoLucia, Lo CaputoSergio, MagnascoLaura, BrianoFederica, PolisenoMariacristina, BrunoSerena Rita, FerraraSergio, PincinoRachele, SarteschiGiovanni, BeltraminiSabrina, SassoElisabetta, MoraSara, GiacominiMauro, BassettiMatteo, Di BiagioAntonio

Durable treatment
Effective for HIV
Discontinuation risk

Rilpivirine (RPV) is a medication used to treat HIV infection. This retrospective study assessed the rate of discontinuation of the RPV single-tablet regimen (STR) and identified factors associated with the risk of discontinuation. The authors found that the discontinuation rate of RPV-STR was 7.7 per 100 person-years. The most common reasons for discontinuation were loss to follow-up, side effects, and ART optimization. Heterosexual and mother-to-child transmission of HIV infection and a history of previous virological failure were associated with a higher risk of discontinuation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

6.

Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.

Author: NeilanAnne M, LandovitzRaphael J, LeMylinh H, GrinsztejnBeatriz, FreedbergKenneth A, McCauleyMarybeth, WattananimitgulNattanicha, CohenMyron S, CiaranelloAndrea L, ClementMeredith E, ReddyKrishna P, HyleEmily P, PaltielA David, WalenskyRochelle P

CAB-LA
HIV prevention
Price premium

Long-acting injectable cabotegravir (CAB-LA) for HIV preexposure prophylaxis (PrEP) could achieve an incremental cost-effectiveness ratio (ICER) of at most $100,000 per quality-adjusted life-year (QALY) compared with generic emtricitabine-tenofovir disoproxil fumarate (F/TDF).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?

Author: WoodBrian R, HuhnGregory D

Weight management
Mitochondrial toxicity
Weight gain

This review discusses the potential causes of weight gain associated with antiretroviral (ARV) drugs used to treat HIV. The review suggests that older ARVs may suppress weight gain, while newer ARVs, such as integrase inhibitors, may promote weight gain.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.

Author: Rotea-SalvoSandra, Martínez-PradedaAlejandro, Fernández-OliveiraCarla, Giménez-ArufeVictor, Balboa-BarreiroVanesa, Margusino-FramiñánLuis, Mena-De-CeaÁlvaro, Vázquez-RodríguezPilar, Castro-IglesiasÁngeles, López-CalvoSoledad, Martín-HerranzIsabel, Míguez-ReyEnrique, Cid-SilvaPurificación

Renal safety
Adverse events

This retrospective observational study evaluated modifications in the renal safety profile of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) in a large real-world cohort of HIV-infected patients. The results showed that serum creatinine improved in both groups among experienced patients, while it remained stable in naive patients. Statistically significant differences in serum creatinine were observed between the two treatment groups, with EVG/c/FTC/TAF showing a lower serum creatinine level.

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Tenofovir alafenamide nephrotoxicity: a case report and literature review.

Author: UeaphongsukkitThornthun, GatechompolSivaporn, AvihingsanonAnchalee, SurintrspanontJerasit, IampenkhaeKroonpong, AvihingsanonYingyos, UdomkarnjananunSuwasin

HIV-1 treatment
TAF
renal and bone outcomes
TAF side effects
acute kidney injury

Tenofovir alafenamide (TAF) has emerged as a preferred drug for treating HIV-1 and chronic hepatitis B infection, but sporadic cases of acute kidney injury in patients using TAF have started to emerge.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Update on Adverse Effects of HIV Integrase Inhibitors.

Author: KolakowskaAgnieszka, MarescaAnaenza Freire, CollinsIntira Jeannie, CailholJohann

Improved HIV treatment
Neuropsychiatric events
Weight gain

Integrase strand transfer inhibitors (INSTIs) are commonly used to treat HIV infection. This review summarizes recent studies on the neuropsychiatric and weight gain side effects of INSTIs in adults, pregnant women, and children/adolescents.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

15.

Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review.

Author: de FragaRaquel Scherer, Van VaisbergVictor, MendesLuiz Cláudio Alfaia, CarrilhoFlair José, OnoSuzane Kioko

Hepatitis B treatment
Abdominal pain
Fatigue
Headache
Nasopharyngitis

Nucleos(t)ide analogs (NAs) are widely used to treat chronic hepatitis B (CHB) and are generally safe, with a low incidence of adverse events (AEs). The most common AEs reported in this review were abdominal pain/discomfort, nasopharyngitis/upper respiratory tract infections, fatigue, and headache. Tenofovir alafenamide (TAF) had the highest density of AEs per patient treated, but more research is needed to confirm its safety profile.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

16.

The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.

Author: StellbrinkH-J, LazzarinA, WoolleyI, LlibreJ M

HIV treatment
STR treatment
Comorbidities
Drug side effects

Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), a single-tablet regimen for HIV, offers a high barrier against resistance and is non-inferior to other regimens in terms of efficacy, making it a valuable option for managing HIV-related comorbidities.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

17.

Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide.

Author: ShafranS D, Di PerriG, EsserS, LelièvreJ-D, ParczewskiM

HIV treatment improvement
Improved safety profile

This study discusses the use of tenofovir alafenamide (TAF) as a safer alternative to tenofovir disoproxil fumarate (TDF) in antiretroviral therapy (ART) for HIV-infected patients. TAF has been shown to have improved renal and bone safety while maintaining efficacy, making it a preferred option for HIV patients, especially as the population ages and comorbidities become more common.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date.

Author: HillLucas, SmithShawn R, KarrisMaile Young

HIV treatment

This review focuses on the data supporting the use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of HIV infection, highlighting its efficacy, tolerability, and potential limitations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

19.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

Author: DaarEric S, DeJesusEdwin, RuanePeter, CrofootGordon, OguchiGodson, CreticosCatherine, RockstrohJürgen K, MolinaJean-Michel, KoenigEllen, LiuYa-Pei, CustodioJoseph, AndreattaKristen, GrahamHiba, ChengAndrew, MartinHal, QuirkErin

Avoid drug interactions
Avoid unwanted side effects
High barrier to resistance
Simplified once-daily
single-tablet regimen

Switching virologically suppressed adults with HIV-1 infection from a boosted protease inhibitor therapy to bictegravir, emtricitabine, and tenofovir alafenamide is a safe and effective option that simplifies the regimen and avoids drug interactions.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Author: MolinaJean-Michel, WardDouglas, BrarIndira, MillsAnthony, StellbrinkHans-Jürgen, López-CortésLuis, RuanePeter, PodzamczerDaniel, BrinsonCynthia, CustodioJoseph, LiuHui, AndreattaKristen, MartinHal, ChengAndrew, QuirkErin

Efficacy
No treatment-emergent resistance
Similar bone
renal
and lipid profiles
Tolerability

Switching virologically suppressed adults with HIV-1 infection from dolutegravir, abacavir, and lamivudine to bictegravir, emtricitabine, and tenofovir alafenamide is a safe and effective option that maintains a high barrier to resistance and provides a simplified regimen.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

21.

Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.

Author: ButiMaria, Riveiro-BarcielaMar, EstebanRafael

CHB treatment
Drug resistance

This review compares the long-term efficacy and safety of entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) in the treatment of chronic hepatitis B (CHB). All three drugs are highly effective, but TAF offers a more favorable safety profile.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

22.

Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B.

Author: WongG L-H, SetoW-K, WongV W-S, YuenM-F, ChanH L-Y

Nucleoside analogues for CHB
TAF renal and bone safety
Adefovir bone toxicity
Adefovir nephrotoxicity
Telbivudine muscular toxicity

Long-term safety profiles of nucleoside analogues are better defined, with the new nucleotide analogue TAF demonstrating favorable renal and bone safety compared to TDF.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

24.

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

Author: OrkinChloe, MolinaJean-Michel, NegredoEugenia, ArribasJosé R, GatheJoseph, EronJoseph J, Van LanduytErika, LathouwersErkki, HufkensVeerle, PetrovicRomana, VanveggelSimon, OpsomerMagda,

Reduced pill burden
Single-tablet regimen
Side effects

This study investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate in people living with HIV.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

26.

A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.

Author: AngioneSara A, CherianSibyl M, ÖzdenerAyşe Elif

Manage HIV-1 infection
Bone mineral density loss
Metabolic effects
Renal impairment

This review examines the efficacy and safety of Genvoya®, a single-tablet regimen for HIV-1 infection, comparing it to regimens containing tenofovir disoproxil fumerate (TDF). It explores the impact of Genvoya® on renal impairment, bone mineral density, metabolic effects, and other adverse events.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

27.

The role of tenofovir alafenamide in future HIV management.

Author: AntelaA, AguiarC, CompstonJ, HendryB M, BoffitoM, MallonP, Pourcher-MartinezV, Di PerriG

Improved bone safety
Improved renal safety
Viral suppression

Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir with high antiviral efficacy and improved renal and bone safety compared to tenofovir disoproxil fumarate (TDF). Clinical data suggest that elvitegravir, cobicistat, emtricitabine, and TAF (E/C/F/TAF) as a single-tablet regimen offers highly effective viral suppression and a favorable safety profile for managing HIV infection, especially in patients with existing renal impairment and adolescents.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

28.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

Author: MillsAnthony, ArribasJose R, Andrade-VillanuevaJaime, DiPerriGiovanni, Van LunzenJan, KoenigEllen, ElionRichard, CavassiniMatthias, MadrugaJose Valdez, BrunettaJason, ShamblawDavid, DeJesusEdwin, OrkinChloe, WohlDavid A, BrarIndira, StephensJeffrey L, GirardPierre-Marie, HuhnGregory, PlummerAndrew, LiuYa-Pei, ChengAndrew K, McCallisterScott,

Reduced side effects
Bone mineral density
Renal toxicity

This study compared the efficacy, safety, and tolerability of switching to a regimen containing tenofovir alafenamide versus remaining on tenofovir disoproxil fumarate. Tenofovir alafenamide reduces tenofovir plasma concentrations by 90%, potentially decreasing off-target side effects. The study aimed to determine if switching to tenofovir alafenamide would maintain efficacy while improving safety and tolerability.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.